Disease burden in patients with type 2 diabetes is largely driven by the associated long-term complications, making glycemic control an invaluable treatment goal. In 2005, the first incretin-based agent was introduced into the type 2 diabetes treatment landscape to address postprandial glucose control. In the postprandial phase to control meal-related glycemic fluctuations, gut enteroendocrine cells release incretins, such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP). This results in glucose-dependent secretion of insulin and suppression of glucagon secretion; impaired insulin response to GLP-1 and GIP in patients with type 2 diabetes contributes to hyperglycemia. Thus, incretin-based therapy has become a popular choice for controlling blood glucose levels because of its glycemic efficacy, ease of use, and low risk for hypoglycemia.
How familiar are you with this therapeutic approach to type 2 diabetes? Test your knowledge with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - May 16, 2022.